ASTELLAS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,506 JPY | +3.51% |
|
+1.72% | -10.68% |
| 04-25 | Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024 | |
| 04-25 | Astellas Pharma Inc. Announces Board and Committee Retirements | CI |
| Sales 2024 | 1,604B 10.12B 13.84B | Sales 2025 * | 1,665B 10.51B 14.37B | Capitalization | 2,700B 17.05B 23.3B |
|---|---|---|---|---|---|
| Net income 2024 | 17.04B 108M 147M | Net income 2025 * | 106B 667M 911M | EV / Sales 2024 | 1.84 x |
| Net Debt 2024 * | 503B 3.18B 4.34B | Net Debt 2025 * | 512B 3.23B 4.42B | EV / Sales 2025 * | 1.93 x |
| P/E ratio 2024 |
173
x | P/E ratio 2025 * |
25.7
x | Employees | 14,484 |
| Yield 2024 * |
4.69% | Yield 2025 * |
4.93% | Free-Float | 98.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Astellas Pharma Inc.
More recommendations
More press releases
More news
| 1 day | +3.51% | ||
| 1 week | +1.72% | ||
| Current month | -8.37% | ||
| 1 month | -11.02% | ||
| 3 months | -10.78% | ||
| 6 months | -21.91% | ||
| Current year | -10.68% |
1 week
1 446.00
1 509.00
1 month
1 426.001 671.00
Current year
1 426.001 801.50
1 year
1 426.002 360.50
3 years
1 426.002 360.50
5 years
1 375.002 360.50
10 years
1 130.002 360.50
| Managers | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 10-31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 19-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 11.47% | 15 M€ | +7.34% | ||
| 2.09% | 251 M€ | +13.17% | ||
| 2.01% | 57 M€ | +19.27% | ||
| 1.99% | 11 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,506 | +3.51% | 13,564,300 |
| 24-04-25 | 1,455 | -0.95% | 8,318,300 |
| 24-04-24 | 1,469 | -1.51% | 10,715,000 |
| 24-04-23 | 1,492 | +1.05% | 6,786,600 |
| 24-04-22 | 1,476 | -0.30% | 8,068,600 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am
More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,506
JPY
Average target price
2,025
JPY
Spread / Average Target
+34.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.68% | 17.15B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4503 Stock
